Solid Biosciences Shares Decline Despite Regulatory Milestone
Published on 12/01/2025 at 20:21 | Redaktion boerse-global.de
Shares of Solid Biosciences traded lower on Monday, shedding as much as 3.6% in value even as the biotechnology firm announced a significant regulatory achievement. The U.S. Food and Drug Administration (FDA) granted its gene therapy candidate, SGT-212, the coveted Rare Pediatric Disease Designation. The market’s skeptical reaction pushed the stock price to a range between $5.23 and $5.26 in early afternoon trading, giving the company a market capitalization of approximately $423 million.
The FDA’s designation applies specifically to SGT-212, an investigational gene therapy targeting Friedreich’s ataxia, a neurodegenerative condition. The therapy’s mechanism involves delivering a full frataxin gene using a dual-administration method: one injection targets the Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
